The PALOMA-1/TRIO-18 data and the regulatory approval of palbociclib represent the first novel non-endocrine therapy to improve PFS in the front-line setting of postmenopausal women with ER+/HER2– advanced breast cancer. The gene discussed is ESR1; the disease is breast cancer.